Navigation Links
HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results

FRAMINGHAM, Mass. and SYDNEY, Feb. 15, 2011 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) will release financial results for the fourth quarter and year ended December 31, 2010 prior to the open of the U.S. stock markets on Thursday, February 24, 2011.

A conference call with management is scheduled for 8:00 am U.S. Eastern Standard Time on Thursday, February 24, 2011 (being midnight Australian Eastern Daylight Time, between February 24 and February 25, 2011) to discuss the Company's financial results, highlights from the quarter and full year, and business outlook.  The call may be accessed by dialing 1-877-941-2322 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial + 1-480-629-9715.

A live webcast of the call will also be available at the Company's website ( by selecting "HeartWare Fourth Quarter Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's web site,

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.For further information:Christopher TaylorHeartWare International, Inc.Email: ctaylor@heartwareinc.comPhone: +1 508 739 0864

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
2. HeartWare International, Inc. Temporary Suspension of Trading
3. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
6. Par Pharmaceutical Reports Second Quarter 2008 Results
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. Pharmos Corporation Reports 2008 Second Quarter Results
9. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
10. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
11. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):